OX40 和 PD-1 联合治疗：为什么 OX40 应优先使用？
On OX40 and PD-1 Combination: Why Should OX40 Be First in Sequence?
机构信息
Molecular Immunology Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
出版信息
Clin Cancer Res. 2017 Oct 15;23(20):5999-6001. doi: 10.1158/1078-0432.CCR-17-2332.
Abstract
The larger fraction of patients treated with immune checkpoint inhibitors remain nonresponding eventually. Combination of checkpoint inhibitor and costimulatory antibodies is thought additive, but for such effect, they may require to be given in the right sequence. .
摘要
大多数接受免疫检查点抑制剂治疗的患者最终仍无反应。检查点抑制剂和共刺激抗体的联合应用被认为是增效的，但为了达到这种效果，它们可能需要按正确的顺序给药。
Zotero 插件